U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07458672) titled 'TAVR for Aortic Regurgitation Under TTE Guidance' on March 01.
Brief Summary: Transcatheter aortic valve replacement (TAVR) is an established therapy for severe aortic valve disease, yet conventional workflows rely on fluoroscopy and iodinated contrast, exposing patients and operators to ionizing radiation and posing challenges for individuals with chronic kidney disease, contrast allergy, or other contraindications. In patients with native aortic regurgitation, the absence of annular/leaflet calcification and frequent annular dilation can further complicate device positioning and anchoring, increasing the procedural dependence on ...